Resveratrol: Stilbene Polyphenol for Cardiovascular, Longevity & Metabolic Health
⚡ 60-Second Summary
Resveratrol (trans-resveratrol, 3,4',5-trihydroxystilbene) is a stilbenoid polyphenol produced by plants as a defense against pathogen stress. Found in red wine (skin of grapes), mulberries, peanuts, and Japanese knotweed (Polygonum cuspidatum — the primary supplement source), resveratrol gained scientific interest through the 'French paradox' hypothesis linking moderate red wine consumption to lower cardiovascular disease rates.
Best-evidenced effects: sirtuin activation (SIRT1) — the molecular switch linked to caloric restriction longevity effects — AMPK stimulation, endothelial function improvement and blood pressure reduction in human RCTs, modest anti-inflammatory effects (IL-6, TNF-α reduction), and metabolic effects in obesity and metabolic syndrome. Low bioavailability (<1%) limits clinical magnitude of effects at standard doses.
Resveratrol's clinical impact is limited by poor bioavailability — it undergoes rapid hepatic and intestinal glucuronidation and sulfation, meaning most consumed resveratrol is rapidly metabolized before reaching target tissues. This is why doses of 500–1000 mg are commonly used when mechanistic studies use micromolar concentrations achievable with much lower doses of a better-absorbed compound.
What is Resveratrol?
Resveratrol surged into public consciousness through David Sinclair's 2003 Nature paper demonstrating SIRT1 activation and lifespan extension in yeast, followed by a 2006 Nature paper showing improved metabolic health and extended lifespan in obese mice. The compound became central to the longevity supplement industry despite subsequent human translational challenges.
Multiple pharmaceutical companies have investigated high-dose resveratrol for clinical applications; SRT1720 and SRT2104 (sirtuin activators) were developed but faced challenges in clinical trials.
Evidence-based benefits
Cardiovascular and Endothelial Function
Multiple meta-analyses of human RCTs (Mousavi et al., 2019; Fogacci et al., 2018) confirm resveratrol significantly reduces systolic and diastolic blood pressure (approximately 2–5 mmHg), reduces LDL cholesterol, and improves flow-mediated dilation (endothelial function marker). Effects are more consistent at higher doses (500–1000 mg/day) and in cardiovascular risk populations.
Metabolic Effects and Insulin Sensitivity
A systematic review of 21 RCTs (Liu et al., 2014) found resveratrol improved insulin sensitivity, fasting glucose, and HbA1c in type 2 diabetics but not in healthy adults. Higher doses (≥500 mg/day) appear to produce more consistent metabolic effects. Several studies show improved adipokine profiles in obesity.
SIRT1 Activation and Longevity Pathways
Human studies confirm resveratrol activates SIRT1 in skeletal muscle and adipose tissue at 2 g/day doses. SIRT1 activation mimics caloric restriction effects on mitochondria and metabolic regulation. Whether this translates to meaningful human longevity extension is completely unknown — long-term human longevity data doesn't exist for any supplement.
Anti-inflammatory Effects
Multiple human RCTs show resveratrol reduces CRP, IL-6, TNF-α, and NF-κB activity. A 2015 meta-analysis confirmed anti-inflammatory effects across multiple conditions. Most consistent in metabolic syndrome and inflammatory disease states.
Supplement forms compared
| Form | Typical dose / Bioavailability | Best for | Notes |
|---|---|---|---|
| Form | Dose | Best For | Notes |
| Trans-Resveratrol (standard) | 250–1000 mg/day | Cardiovascular and metabolic effects | Bioavailability <1%; standard supplement form; most human trials use this |
| Micronized/Nano Resveratrol | 250–500 mg/day | Improved bioavailability — fewer human trials available | Particle size reduction increases absorption area; some studies show 2–5x bioavailability improvement |
| Pterostilbene + Resveratrol Combo | Ptero 50 mg + Resv 20 mg (twice daily) | Complementary stilbene pairing for longevity applications | Pterostilbene provides better pharmacokinetics; resveratrol provides established SIRT1 evidence |
| Resveratrol + NMN (David Sinclair Stack) | Resv 500 mg + NMN 500–1000 mg | Longevity-focused combination | Popularized by Sinclair's personal protocol; not specifically RCT-tested as combination |
How much should you take?
- 500–1000 mg/day trans-resveratrol for cardiovascular and metabolic effects (most effective dose in human trials)
- Take with a fatty meal to improve absorption (fat-soluble compound)
- 250 mg/day as a lower-dose option for general antioxidant use, though metabolic evidence favors higher doses
- Combine with pterostilbene (50 mg) for improved bioavailability of the stilbene class
Trans-resveratrol from Polygonum cuspidatum (Japanese knotweed root) is the standard supplement source. Look for >98% trans-resveratrol purity (the cis isomer is biologically inactive). Japanese knotweed source is relevant for people with plant allergies. Micronized or liposomal forms may improve bioavailability but have less human trial validation.
Safety and side effects
Common side effects
- Generally well-tolerated at 500–1000 mg/day in human trials
- GI discomfort (nausea, diarrhea, loose stools) at high doses >2 g/day
- Possible mild estrogenic effects at very high doses (stilbene class) — theoretical concern
- A 2014 study found high-dose resveratrol (2 g/day, 8 weeks) REDUCED exercise-induced health benefits in trained men — possible antioxidant excess blunting training adaptation
Serious risks
The antioxidant paradox is relevant for resveratrol: very high doses may blunt exercise adaptations by suppressing beneficial ROS signaling. This doesn't apply at standard doses (250–1000 mg) but is relevant for athletes using mega-doses around training.
Drug and nutrient interactions
- Warfarin and anticoagulants — resveratrol inhibits CYP2C9; can increase warfarin levels and bleeding risk; monitor INR
- Statins (simvastatin, atorvastatin) — CYP3A4 inhibition may increase statin levels; monitor
- Tamoxifen — estrogenic activity could theoretically interfere; consult oncologist
- NSAIDs and antiplatelet drugs — additive platelet inhibition; monitor at high resveratrol doses
Check our free interaction checker for additional combinations.
Who might benefit — and who should use caution
| Most likely to benefit | Use with caution or seek guidance |
|---|---|
| Adults with cardiovascular risk factors (elevated blood pressure, LDL, metabolic syndrome) | Athletes doing intense training — very high doses may blunt training adaptation; use moderate doses |
| Older adults interested in NAD+/sirtuin longevity approaches with dietary polyphenols | People on warfarin — significant CYP2C9 interaction; requires INR monitoring |
| Individuals with type 2 diabetes or insulin resistance seeking metabolic support | Hormone-sensitive cancer patients — estrogenic activity; consult oncologist |
| People interested in the French paradox cardiovascular benefit in supplement form |
Frequently asked questions
What happened to resveratrol as the longevity miracle drug?
The initial excitement from Sinclair's 2003–2006 papers was tempered by translational challenges: resveratrol's <1% bioavailability limits how much active compound reaches tissues; GlaxoSmithKline's sirtuin activator drug pipeline (SRT2104) showed modest benefits in human trials; and a 2014 Journal of Health and Aging study of healthy Italians eating a resveratrol-rich diet found no mortality benefit. Current scientific consensus: resveratrol has real cardiovascular and metabolic benefits in humans, but the 'fountain of youth' framing was premature.
Is red wine an effective source of resveratrol?
Red wine contains approximately 0.5–2 mg resveratrol per glass — compared to supplement doses of 250–1000 mg. A single glass provides 1/500th of a typical supplement dose. The cardiovascular benefits of moderate red wine consumption are likely mediated by multiple compounds (alcohol, flavanols, polyphenols) rather than resveratrol specifically. Drinking enough wine to match supplement resveratrol doses would be profoundly harmful.
What is the difference between resveratrol and pterostilbene?
Both are stilbene polyphenols with SIRT1-activating properties, but with critical pharmacokinetic differences: resveratrol has <1% bioavailability (rapid conjugation); pterostilbene achieves ~80% bioavailability (methyl groups block conjugation). Resveratrol has thousands of human studies; pterostilbene has handful of RCTs but with confirmed blood pressure benefits. Pairing them exploits complementary pharmacokinetics — pterostilbene for persistent tissue exposure, resveratrol for well-documented SIRT1 and cardiovascular effects.
Should I take resveratrol with or without food?
Take with a fatty meal. Resveratrol is fat-soluble; lipid absorption pathways significantly improve its bioavailability. Studies show 3–5x higher plasma resveratrol concentrations when consumed with a high-fat meal versus fasted. This is one of the few practical bioavailability strategies available for standard non-micronized resveratrol.
Related ingredients
Pterostilbene
Bioavailable stilbene analog — complementary longevity polyphenol.
NMN
Complementary NAD+ longevity supplement for the Sinclair longevity stack.
Quercetin
Broad-spectrum flavonoid often combined in polyphenol longevity stacks.
Disclaimer: This information is for educational purposes only and should not replace medical advice. Always consult a qualified healthcare provider before starting any supplement, especially if you have a medical condition, are pregnant, or take prescription medications. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.